Cytokinetics EVP Malik sells 3,500 shares under plan

The post-exercise position reported for CYTOKINETICS INC's EVP Research & Development was 16,386 non-qualified stock options; the transactions were under a Rule 10b5-1 plan.

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) EVP Research & Development Fady Ibraham Malik exercised options to acquire 3,500 common shares on October 20, 2026, at an exercise price of $7.80 per share, then sold 3,500 shares at $64.01 per share under a Rule 10b5-1 plan. The option position following the exercise was reported as 16,386 options.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,500 shares ($197K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($224K)

Approx. gross sale proceeds $224K

Approx. exercise cost $27K

Approx. pre-tax spread $197K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$64.01	$224K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 16,386 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Options exercised: 3,500 options Exercise price: $7.80 per share Common shares acquired: 3,500 shares +3 more

6 metrics

Options exercised 3,500 options Exercise on October 20, 2026

Exercise price $7.80 per share Options exercised on October 20, 2026

Common shares acquired 3,500 shares October 20, 2026

Common shares sold 3,500 shares October 20, 2026

Sale price $64.01 per share Sale on October 20, 2026

Non-qualified stock options following exercise 16,386 options Following the October 20, 2026 exercise

Key Terms

Non-Qualified Stock Option (Right to Buy), Rule 10b5-1 plan, derivative security

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"Non-Qualified Stock Option (Right to Buy)"

Rule 10b5-1 plan financial

"transactions under a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did Fady Ibraham Malik sell, and at what price?

Fady Ibraham Malik, EVP Research & Development at CYTOKINETICS INC, sold 3,500 common shares at $64.01 per share on October 20, 2026. He also exercised options to acquire 3,500 shares at $7.80 per share under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:21 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/20/2026		M		3,500	A	$7.8	157,402	D
Common Stock	10/20/2026		S		3,500	D	$64.01	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	10/20/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	16,386	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)